1,003.57
price down icon0.41%   -4.16
after-market After Hours: 1001.99 -1.58 -0.16%
loading
Lilly Eli Co stock is traded at $1,003.57, with a volume of 1.96M. It is down -0.41% in the last 24 hours and down -9.35% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,007.73
Open:
$1011.63
24h Volume:
1.96M
Relative Volume:
0.61
Market Cap:
$896.18B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
44.43
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-2.46%
1M Performance:
-9.35%
6M Performance:
+35.09%
1Y Performance:
+10.15%
1-Day Range:
Value
$993.66
$1,015.66
1-Week Range:
Value
$993.66
$1,056.20
52-Week Range:
Value
$623.78
$1,133.95

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
50,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, NVS, AZN

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
LLY
Lilly Eli Co
1,003.57 899.90B 65.18B 20.64B 5.96B 22.59
Drug Manufacturers - General icon
JNJ
Johnson Johnson
245.30 594.64B 94.19B 26.80B 19.70B 11.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
236.19 413.50B 61.16B 4.19B 17.82B 2.3614
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
165.15 313.28B 54.72B 14.02B 15.32B 7.1855
Drug Manufacturers - General icon
AZN
Astrazeneca Plc
201.53 312.88B 58.80B 10.24B 8.98B 3.2788

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-07-26 Resumed UBS Buy
Dec-16-25 Upgrade Daiwa Securities Neutral → Buy
Dec-15-25 Reiterated BofA Securities Buy
Dec-15-25 Reiterated Goldman Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-10-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
03:05 AM

Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others. - marketscreener.com

03:05 AM
pulisher
11:31 AM

Eli Lilly and booming weight-loss pharma industry now 20% of Irish goods exports - Irish Examiner

11:31 AM
pulisher
10:23 AM

Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq - Investing.com India

10:23 AM
pulisher
10:01 AM

Eli Lilly Unusual Options Activity For March 04 - Benzinga

10:01 AM
pulisher
07:21 AM

Richard C. Young & CO. LTD. Makes New $13.88 Million Investment in Eli Lilly and Company $LLY - MarketBeat

07:21 AM
pulisher
06:45 AM

Picton Mahoney Asset Management Lowers Holdings in Eli Lilly and Company $LLY - MarketBeat

06:45 AM
pulisher
05:48 AM

GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.

05:48 AM
pulisher
12:51 PM

2 Top Growth Stocks to Buy in the First Half of 2026 - AOL.com

12:51 PM
pulisher
Mar 03, 2026

Does Lilly’s Broad Pipeline Wins in Obesity and Immunology Reshape the Bull Case for LLY? - simplywall.st

Mar 03, 2026
pulisher
Mar 03, 2026

2 Top Growth Stocks to Buy in the First Half of 2026 - The Motley Fool

Mar 03, 2026
pulisher
Mar 03, 2026

Eli Lilly and Company (NYSE:LLY) Shares Down 1%Should You Sell? - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Eli Lilly (LLY) Monitored as FDA Targets Telehealth Firms for Mi - GuruFocus

Mar 03, 2026
pulisher
Mar 03, 2026

Eli Lilly & Co. stock underperforms Tuesday when compared to competitors - MarketWatch

Mar 03, 2026
pulisher
Mar 03, 2026

Eli Lilly and Company $LLY Shares Bought by Victory Capital Management Inc. - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Lilly in the Valley: An Inside Look at Eli Lilly’s Lehigh Valley Investment - Fairfield Sun Times

Mar 03, 2026
pulisher
Mar 03, 2026

Eli Lilly and Company $LLY Stock Position Lowered by State Farm Mutual Automobile Insurance Co. - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

William Blair Investment Management LLC Lowers Holdings in Eli Lilly and Company $LLY - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

South Dakota Investment Council Has $43.08 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly and Company

Mar 03, 2026
pulisher
Mar 02, 2026

Eli Lilly and Company (NYSE:LLY) Trading Down 3.2%Time to Sell? - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Fisher Asset Management Boosts Eli Lilly Stake - National Today

Mar 02, 2026
pulisher
Mar 02, 2026

First Long Island Investors Boosts Eli Lilly Stake - National Today

Mar 02, 2026
pulisher
Mar 02, 2026

Tech giants see a cure for cancer in AI. But Eli Lilly’s CEO finds it ‘not particularly good’ at solving biology or chemistry problems - AOL.com

Mar 02, 2026
pulisher
Mar 02, 2026

Eli Lilly and Co Stock Closed Down by 3.27% on Mar 2: Facts Behind the Movement - TradingKey

Mar 02, 2026
pulisher
Mar 02, 2026

Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval - Reuters

Mar 02, 2026
pulisher
Mar 02, 2026

Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock? - AOL.com

Mar 02, 2026
pulisher
Mar 02, 2026

Eli Lilly sees a dip — What is pressuring the stock - Traders Union

Mar 02, 2026
pulisher
Mar 02, 2026

What Smart Money Loves About Lilly - 24/7 Wall St.

Mar 02, 2026
pulisher
Mar 02, 2026

Kingsview Wealth Management LLC Raises Stake in Eli Lilly and Company $LLY - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

First Long Island Investors LLC Increases Holdings in Eli Lilly and Company $LLY - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Park Square Financial Group LLC Sells 1,356 Shares of Eli Lilly and Company $LLY - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Geneva Partners LLC Sells 1,884 Shares of Eli Lilly and Company $LLY - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Eli lilly’s $5 billion pharmaceutical plant to boost gooachland and central virginia - Virginia Business

Mar 02, 2026
pulisher
Mar 02, 2026

Antibiotics Market - GlobeNewswire Inc.

Mar 02, 2026
pulisher
Mar 02, 2026

Aviso Financial Inc. Acquires 1,236 Shares of Eli Lilly and Company $LLY - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

How America’s former steel heartland secured a $3.5bn Eli Lilly facility - Pharmaceutical Technology

Mar 02, 2026
pulisher
Mar 02, 2026

LLY Stock Price, Quote & Chart | ELI LILLY & CO (NYSE:LLY) - ChartMill

Mar 02, 2026
pulisher
Mar 02, 2026

Eli Lilly and Company (NYSE:LLY) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Mar 02, 2026
pulisher
Mar 01, 2026

Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave - The Economic Times

Mar 01, 2026
pulisher
Mar 01, 2026

Laurel Wealth Advisors LLC Lowers Stake in Eli Lilly and Company $LLY - MarketBeat

Mar 01, 2026
pulisher
Mar 01, 2026

Finemark National Bank & Trust Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat

Mar 01, 2026
pulisher
Mar 01, 2026

Artisan Partners Limited Partnership Grows Stock Position in Eli Lilly and Company $LLY - MarketBeat

Mar 01, 2026
pulisher
Feb 28, 2026

Huntington National Bank Has $199.95 Million Holdings in Eli Lilly and Company $LLY - MarketBeat

Feb 28, 2026
pulisher
Feb 28, 2026

Ibex Wealth Advisors Sells 5,897 Shares of Eli Lilly and Company $LLY - MarketBeat

Feb 28, 2026
pulisher
Feb 28, 2026

Eli Lilly and Company $LLY Shares Bought by Power Wealth Management LLC - MarketBeat

Feb 28, 2026
pulisher
Feb 28, 2026

Eli Lilly and Company $LLY Position Boosted by Clal Insurance Enterprises Holdings Ltd - MarketBeat

Feb 28, 2026
pulisher
Feb 28, 2026

American Century Companies Inc. Acquires 120,905 Shares of Eli Lilly and Company $LLY - MarketBeat

Feb 28, 2026
pulisher
Feb 27, 2026

Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy campus - Indiana Economic Digest

Feb 27, 2026
pulisher
Feb 27, 2026

Eli Lilly and Company (NYSE:LLY) Trading Up 2.8% Following Analyst Upgrade - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch

Feb 27, 2026
pulisher
Feb 27, 2026

Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable (NYSE:NVO) - Seeking Alpha

Feb 27, 2026

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$245.30
price down icon 0.59%
$236.19
price up icon 1.00%
drug_manufacturers_general NVS
$165.15
price up icon 0.59%
drug_manufacturers_general AZN
$201.53
price down icon 0.11%
drug_manufacturers_general MRK
$120.28
price up icon 0.38%
Cap:     |  Volume (24h):